PTGX - Protagonist Therapeutics, Inc.
| Previous Close | 8.82 |
| Open | 8.96 |
| Bid | 3.89 x 1800 |
| Ask | 9.35 x 800 |
| Day's Range | 8.45 - 8.96 |
| 52 Week Range | 5.50 - 23.97 |
| Volume | 51,292 |
| Avg. Volume | 261,120 |
| Market Cap | 208.34M |
| Beta (3Y Monthly) | 3.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.22 |
| Earnings Date | Nov 5, 2018 - Nov 9, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.67 |
- GlobeNewswire•11 days ago
Report: Developing Opportunities Within Apollo Investment, Ladder Capital, Medpace, MPLX LP, Silicon Laboratories, and Protagonist Therapeutics — Future Expectations, Projections Moving into 2018
NEW YORK, Oct. 10, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire•13 days ago
Protagonist Therapeutics Announces Acceptance of Late Breaking Abstract for PTG-100 at the United European Gastroenterology Week Meeting
NEWARK, Calif. , Oct. 8, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that Dr. William J. Sandborn will present clinical data from a Phase 2 study of PTG-100, the Company's ...
- PR Newswire•24 days ago
Protagonist Therapeutics Announces Fast Track Designation Granted by U.S. FDA to Hepcidin Mimetic PTG-300
NEWARK, Calif., Sept. 27, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (PTGX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to therapeutic candidate PTG-300 for the treatment of chronic anemia due to ineffective erythropoiesis in patients with beta-thalassemia. PTG-300 is an injectable hepcidin mimetic that has been granted Orphan Drug Designation by the FDA for beta-thalassemia, a rare disease characterized by iron overload.
- PR Newswire•27 days ago
Protagonist Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference Monday, Oct. 1
NEWARK, Calif. , Sept. 24, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will provide a corporate ...
- PR Newswire•last month
Protagonist Therapeutics Reports Granting of Inducement Award
NEWARK, Calif., Sept. 19, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (PTGX) today reported that on Sept. 15, 2018, it issued an inducement award to Carter King, the Company's recently hired Vice President of Business Development, in accordance with the terms of Mr. King's employment offer letter. The award was granted under the Protagonist Therapeutics Inducement Award Plan, which was adopted May 29, 2018. The inducement award consists of an option to purchase 30,000 shares of Protagonist Therapeutics common stock and has a ten-year term.
- PR Newswire•last month
Protagonist Therapeutics Receives $1.45 Million SBIR Funding for the Development of PTG-300
NEWARK, Calif., Sept. 6, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (PTGX) today announced the receipt of a Phase 2 Small Business Innovation Research (SBIR) Grant from the National Heart, Lung and Blood Institute of the National Institutes of Health. This award, Number R44HL132702, provides up to $1.45 million over two years to support research aimed at developing the Company's novel hepcidin mimetic clinical drug for the potential treatment of chronic anemia and iron overload in rare blood disorders, including beta-thalassemia. "This grant recognizes the potential benefit of our hepcidin mimetic PTG-300 in the treatment of blood disorders associated with iron metabolism," said David Liu, Ph.D., Protagonist Therapeutics' Head of R&D and Chief Scientific Officer.
- PR Newswire•last month
Protagonist Therapeutics Expands Intellectual Property Portfolio
-- Three issued U.S. patents add to existing protection for clinical drug candidates derived from Protagonist's innovative peptide technology platform -- NEWARK, Calif. , Sept. 6, 2018 /PRNewswire/ -- ...
- PR Newswire•2 months ago
Protagonist Therapeutics Reports Granting of Inducement Award
NEWARK, Calif., Aug. 17, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (PTGX) today reported that on August 15, 2018, it issued an inducement award to Niall Murphy, the Company's recently hired Vice President, Corporate Controller, in accordance with the terms of Mr. Murphy's employment offer letter. The award was granted under the Protagonist Therapeutics Inducement Award Plan, which was adopted May 29, 2018.
- InvestorPlace•2 months ago
Protagonist Stock Jumps 58% After Re-Review of Test Results
The mouth-watering 58% rise in shares of Protagonist Therapeutics (NASDAQ:PTGX) on Monday should interest biotech investors. At a market cap of $236.2 million, experienced biotech investors will expect higher than normal volatility. On Monday, Protagonist announced that it secured $22 million in equity financing through the sale of 2.75 million shares.
- Zacks•2 months ago
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Tops Revenue Estimates
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -36.67% and 36.54%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Protagonist Therapeutics: 2Q Earnings Snapshot
The Newark, California-based company said it had a loss of 41 cents per share. The biopharmaceutical company posted revenue of $11.7 million in the period. Protagonist Therapeutics shares have fallen 47 ...
- PR Newswire•2 months ago
Protagonist Therapeutics Reports Second Quarter 2018 Financial Results
NEWARK, Calif. , Aug. 7, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported its financial results for the second quarter ended June 30, 2018 . "Protagonist continues ...
- ACCESSWIRE•2 months ago
Today’s Research Reports on Stocks to Watch: Protagonist Therapeutics and Intercept Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Biotech stocks Protagonist Therapeutics and Intercept Pharmaceuticals were heading higher on Monday after positive developments and analyst upgrades. Protagonist ...
- PR Newswire•2 months ago
Final Results from the Protagonist PROPEL Study Support Further Clinical Development of PTG-100 for the Treatment of Ulcerative Colitis
-- Independent blinded re-read of endoscopies provides signal of clinical efficacy and identifies human error in initial reads provided by contract research organization -- -- Protagonist plans to discuss ...
- PR Newswire•2 months ago
Protagonist Therapeutics Secures $22 Million Equity Financing
NEWARK, Calif., Aug. 6, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (PTGX), a biopharmaceutical company leveraging its proprietary technology platform to discover and develop novel peptide-based drugs, today announced that it has signed a securities purchase agreement with investors including BVF Partners L.P. and their affiliates for the sale of 2,750,000 shares of common stock for gross proceeds of $22 million. The investors also received five-year warrants to purchase 1,375,000 shares of common stock at $10.00 per share and 1,375,000 shares of common stock at $15.00 per share. Proceeds from the financing will be used to advance development of drug candidate PTG-100.
- GlobeNewswire•3 months ago
Factors of Influence in 2018, Key Indicators and Opportunity within Protagonist Therapeutics, HD Supply, BIOHAVEN PHARM, Big Lots, Clean Energy Fuels, and H&E Equipment Services — New Research Emphasizes Economic Growth
NEW YORK, Aug. 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Protagonist ...
- PR Newswire•4 months ago
Protagonist Announces Phase 1 and Pre-clinical Data on Hepcidin Mimetic PTG-300 Presented at European Hematology Association Annual Meeting
NEWARK, Calif., June 18, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (PTGX) today announced that results of a Phase 1 study in healthy volunteers and supportive pre-clinical data for the Company's novel injectable hepcidin mimetic, PTG-300, were the subject of oral presentations on June 16, 2018, at the 23rd Congress of the European Hematology Association (EHA) in Stockholm. Protagonist is developing PTG-300 for the treatment of anemia and iron overload in related rare blood disorder diseases, including beta thalassemia.
- PR Newswire•5 months ago
Protagonist Therapeutics to Present at the 2018 JMP Securities Life Sciences Conference
NEWARK, Calif. , June 6, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will provide a corporate ...
- PR Newswire•5 months ago
Protagonist Therapeutics Reports Granting of Inducement Award
NEWARK, Calif., June 1, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (PTGX) today announced that on May 31, 2018, it issued an inducement award to Samuel Saks, M.D., the Company's recently appointed Chief Development Officer, in accordance with the terms of Dr. Saks' employment offer letter. The award was granted under the Protagonist Therapeutics Inducement Award Plan, which was adopted May 29, 2018. The inducement award consists of an option to purchase 50,000 shares of Protagonist Therapeutics common stock and has a ten-year term.
- PR Newswire•5 months ago
Protagonist Therapeutics Names Samuel Saks, M.D., as Chief Development Officer
NEWARK, Calif. , May 24, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced the appointment of Samuel Saks , M.D., as Chief Development Officer. In this newly-created role, ...
- PR Newswire•5 months ago
Protagonist Therapeutics Announces Two Oral Presentations Accepted for 23rd Congress of the European Hematology Association
NEWARK, Calif. , May 17, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced that clinical and preclinical abstracts for PTG-300, the Company's injectable hepcidin mimetic ...
- PR Newswire•5 months ago
Protagonist Therapeutics Appoints Bryan Giraudo to Board of Directors
NEWARK, Calif., May 16, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (PTGX) today announced the appointment of Bryan Giraudo to its Board of Directors. Mr. Giraudo currently serves as Chief Financial Officer of Gossamer Bio and was previously Senior Managing Director at Leerink Partners. "We are excited that Bryan has chosen to join the Protagonist board.
- Associated Press•5 months ago
Protagonist Therapeutics: 1Q Earnings Snapshot
The Newark, California-based company said it had a loss of 36 cents per share. The biopharmaceutical company posted revenue of $10.8 million in the period. Protagonist Therapeutics shares have fallen 60 ...
- PR Newswire•5 months ago
Protagonist Therapeutics Reports First Quarter 2018 Financial Results
NEWARK, Calif. , May 9, 2018 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today reported its financial results for the first quarter ended March 31, 2018 . "Protagonist is continuing ...
